Cardioprotective drug therapies at interview
| Coronary patients (n=676) | High-risk individuals (n=446) | Adjusted difference* % (95% CI); p value | |
| Antiplatelet treatments | 636 (95.4%; 93.8 to 97) | 121 (28.4%; 24.1 to 32.7) | −67% (−71.7 to −62.3); p<0.001 |
| Lipid-lowering drugs | 630 (94.7%; 93 to 96.4) | 273 (62.9%; 58.3 to 67.5) | −31.5% (−36.5 to −26.5); p<0.001 |
| Statins | 617 (92.8%; 90.8 to 94.8) | 265 (61.2%; 56.6 to 65.8) | −31.3% (−36.4 to −26.2); p<0.001 |
| Blood pressure-lowering drugs | 633 (95.3%; 93.7 to 96.9) | 318 (73.4%; 69.2 to 77.6) | −21% (−25.6 to −16.4); p<0.001 |
| β-blockers | 495 (74.8%; 71.5 to 78.1) | 46 (11.3%; 8.2 to 14.4) | −62.8% (−67.6 to −58); p<0.001 |
| ACE inhibitors | 420 (63.3%; 59.6 to 67) | 154 (36.8%; 32.2 to 41.4) | −25.7% (−31.9 to −19.5); p<0.001 |
| ARB | 112 (16.8%; 14.0 to 19.6) | 86 (21%; 17 to 25) | 3.8% (−1.2 to 8.8); p=0.14 |
| Calcium channel blockers | 118 (17.8%; 14.9 to 20.7) | 110 (26.4%; 22.2 to 30.6) | 9.1% (3.7 to 14.5); p=0.001 |
| Diuretics | 128 (19.2%; 16.2 to 22.2) | 104 (25.6%; 21.3 to 29.9) | 7.1% (1.8 to 12.4); p=0.009 |
| Others | 12 (1.8%; 0.8 to 2.8) | 11 (2.7%; 1.1 to 4.3) | 1.1% (−0.9 to 3.1); p=0.27 |
| Anticoagulants | 26 (3.9%; 2.4 to 5.4) | 4 (1.1%; 0 to 2.2) | −2.9% (−4.4 to −1.4); p<0.001 |
Data shown as n (%; 95% CI). Percentages are of non-missing values.
↵* Adjusted for age and sex using binomial regression with log link.
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker.